S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:INCY

Incyte Stock Competitors

$65.78
-0.85 (-1.28%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$65.21
$66.79
50-Day Range
$63.34
$70.37
52-Week Range
$61.91
$101.47
Volume
2.57 million shs
Average Volume
2.20 million shs
Market Capitalization
$14.53 billion
P/E Ratio
27.29
Dividend Yield
N/A
Beta
0.72

Incyte (NASDAQ:INCY) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, ALNY, BMRN, RGEN, and EXAS

Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry.

Incyte vs.

Gilead Sciences (NASDAQ:GILD) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.

Gilead Sciences has higher revenue and earnings than Incyte. Gilead Sciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$24.69 billion3.53$123 million$5.8611.87
Incyte$2.67 billion5.45-$295.70 million$2.4127.29

Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Gilead Sciences received 1249 more outperform votes than Incyte when rated by MarketBeat users. Likewise, 79.27% of users gave Gilead Sciences an outperform vote while only 75.46% of users gave Incyte an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2405
79.27%
Underperform Votes
629
20.73%
IncyteOutperform Votes
1156
75.46%
Underperform Votes
376
24.54%

Gilead Sciences currently has a consensus target price of $124.58, suggesting a potential upside of 79.10%. Incyte has a consensus target price of $88.30, suggesting a potential upside of 34.24%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.67
Incyte
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Gilead Sciences had 4 more articles in the media than Incyte. MarketBeat recorded 7 mentions for Gilead Sciences and 3 mentions for Incyte. Gilead Sciences' average media sentiment score of 0.45 beat Incyte's score of 0.26 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
3 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Incyte
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.1% of Gilead Sciences shares are held by institutional investors. Comparatively, 86.9% of Incyte shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 15.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gilead Sciences has a net margin of 26.91% compared to Incyte's net margin of 18.35%. Gilead Sciences' return on equity of 56.59% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences 26.91% 56.59% 16.36%
Incyte 18.35% 22.27% 16.60%

Summary

Gilead Sciences beats Incyte on 12 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Incyte (NASDAQ:INCY) vs. Its Competitors

TypeIncyteCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$14.72B$5.82B$4.91B$7.73B
Dividend YieldN/A1.20%1.91%2.53%
P/E Ratio27.2917.4922.6122.08
Price / Sales5.45631.752,449.93252.26
Price / CashN/A193.3964.83178.86
Price / Book4.629.126.337.20
Net Income-$295.70M$6.02M$95.98M$154.04M
7 Day Performance-3.80%-5.51%-6.45%-5.41%
1 Month Performance-3.07%-7.99%-14.72%-11.88%
1 Year Performance-20.88%52.81%7.40%21.45%

Incyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
3.0266 of 5 stars
$202.44
-0.6%
$234.20
-15.7%
-11.7%$113.31B$25.42B20.8524,300Dividend Increase
GILD
Gilead Sciences
3.5333 of 5 stars
$69.56
-0.2%
$79.09
-13.7%
+13.0%$87.39B$24.69B11.8713,600
REGN
Regeneron Pharmaceuticals
2.4981 of 5 stars
$635.16
-0.2%
$714.93
-12.6%
+29.0%$68.31B$8.50B10.149,123Insider Selling
VRTX
Vertex Pharmaceuticals
2.1526 of 5 stars
$203.81
-0.3%
$254.19
-24.7%
-10.7%$51.82B$6.21B24.473,400Analyst Report
Short Interest ↓
Analyst Revision
News Coverage
BIIB
Biogen
2.3034 of 5 stars
$223.92
-2.1%
$373.45
-66.8%
-8.9%$33.57B$13.44B21.919,100Analyst Revision
SGEN
Seagen
2.492 of 5 stars
$150.74
-5.3%
$184.36
-22.3%
-15.9%$27.56B$2.18B-81.482,092Insider Selling
ALNY
Alnylam Pharmaceuticals
2.2938 of 5 stars
$171.36
-6.7%
$198.13
-15.6%
+32.3%$21.87B$492.85M-24.031,453Analyst Report
BMRN
BioMarin Pharmaceutical
2.755 of 5 stars
$82.95
-2.1%
$109.43
-31.9%
+4.2%$15.23B$1.86B1,036.883,059Analyst Report
Insider Selling
Analyst Revision
RGEN
Repligen
2.3831 of 5 stars
$262.88
-2.3%
$316.86
-20.5%
+39.6%$14.53B$366.26M125.181,128
EXAS
Exact Sciences
2.3923 of 5 stars
$76.59
-5.2%
$140.38
-83.3%
-42.4%$13.88B$1.49B-15.415,000Gap Up
NVAX
Novavax
2.125 of 5 stars
$160.48
-0.9%
$249.60
-55.5%
+27.1%$12.13B$475.60M-10.84375Insider Selling
Gap Up
UTHR
United Therapeutics
2.4665 of 5 stars
$185.99
-1.8%
$224.38
-20.6%
+39.3%$8.38B$1.48B18.84950Insider Selling
Short Interest ↓
News Coverage
NBIX
Neurocrine Biosciences
2.8529 of 5 stars
$79.68
-1.2%
$116.47
-46.2%
-17.5%$7.56B$1.05B17.44845Analyst Downgrade
Insider Selling
EXEL
Exelixis
2.949 of 5 stars
$15.84
-4.0%
$33.10
-109.0%
-16.5%$5.01B$987.54M31.06773
HALO
Halozyme Therapeutics
2.747 of 5 stars
$32.40
-2.4%
$52.44
-61.9%
-19.2%$4.56B$267.59M11.61136Analyst Report
News Coverage
IONS
Ionis Pharmaceuticals
1.9181 of 5 stars
$26.39
-0.9%
$49.06
-85.9%
-48.5%$3.73B$729M-6.24757News Coverage
ALKS
Alkermes
2.0931 of 5 stars
$22.04
-0.3%
$28.71
-30.3%
+15.5%$3.56B$1.04B-38.002,245Analyst Report
ARNA
Arena Pharmaceuticals
2.2381 of 5 stars
$49.55
-7.3%
$99.56
-100.9%
-26.1%$3.03B$320K-5.11363Analyst Report
FOLD
Amicus Therapeutics
2.0993 of 5 stars
$10.45
-6.5%
$16.56
-58.4%
-54.9%$2.91B$260.89M-11.61483Insider Selling
OPK
OPKO Health
2.2731 of 5 stars
$3.86
-2.8%
$6.00
-55.4%
-18.9%$2.63B$1.44B35.095,269News Coverage
LGND
Ligand Pharmaceuticals
2.3264 of 5 stars
$150.72
-4.1%
$223.75
-48.5%
+74.1%$2.52B$186.42M37.772,018
CCXI
ChemoCentryx
2.3331 of 5 stars
$34.66
-6.9%
$73.43
-111.9%
-39.7%$2.42B$64.89M-19.92133
EBS
Emergent BioSolutions
2.6564 of 5 stars
$41.89
-2.0%
$92.25
-120.2%
-49.4%$2.25B$1.56B9.972,200Short Interest ↓
CDXS
Codexis
1.6798 of 5 stars
$32.56
-5.3%
$32.17
-1.2%
+85.4%$2.11B$69.06M-135.66181
BCRX
BioCryst Pharmaceuticals
2.2014 of 5 stars
$11.44
-3.8%
$20.20
-76.6%
+87.5%$2.05B$17.81M-9.01246
MYGN
Myriad Genetics
1.7115 of 5 stars
$24.38
-4.7%
$30.00
-23.1%
+29.1%$1.95B$638.60M-28.022,700News Coverage
IRWD
Ironwood Pharmaceuticals
2.2831 of 5 stars
$10.98
-1.2%
$14.50
-32.1%
-8.3%$1.80B$389.52M3.38232
CLDX
Celldex Therapeutics
2.2 of 5 stars
$35.68
-5.4%
$59.00
-65.4%
+81.9%$1.66B$7.42M-20.27124
DVAX
Dynavax Technologies
2.5881 of 5 stars
$13.17
-11.6%
$21.00
-59.5%
+155.2%$1.58B$46.55M-37.63245Short Interest ↓
Analyst Revision
News Coverage
Gap Down
IMGN
ImmunoGen
1.8798 of 5 stars
$6.62
-8.2%
$8.90
-34.4%
+10.0%$1.45B$132.30M-19.4779Analyst Report
Short Interest ↓
Analyst Revision
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$78.03
-6.2%
$179.50
-130.0%
-34.1%$1.33BN/A-5.3342
SGMO
Sangamo Therapeutics
1.8881 of 5 stars
$8.10
-4.3%
$23.00
-184.0%
-18.9%$1.18B$118.19M-6.38413Insider Selling
INVA
Innoviva
1.7165 of 5 stars
$16.36
-0.7%
N/A+55.7%$1.14B$336.79M5.245High Trading Volume
MNKD
MannKind
1.6498 of 5 stars
$4.17
-6.0%
$6.30
-51.1%
+41.4%$1.05B$65.14M-13.03241
VNDA
Vanda Pharmaceuticals
2.2581 of 5 stars
$16.22
-2.2%
$19.33
-19.2%
+21.5%$903.65M$248.17M26.59292Insider Selling
News Coverage
AGEN
Agenus
2.1598 of 5 stars
$2.92
-3.4%
$11.00
-276.7%
-12.3%$749.94M$88.17M-24.33359Analyst Upgrade
LXRX
Lexicon Pharmaceuticals
1.9714 of 5 stars
$4.17
-9.8%
$12.00
-187.8%
+163.9%$681.94M$24M-8.6978
ICPT
Intercept Pharmaceuticals
2.4093 of 5 stars
$15.63
-9.0%
$29.67
-89.8%
-55.8%$461.87M$312.69M-4.82498
GERN
Geron
1.7998 of 5 stars
$1.33
-3.8%
$5.50
-313.5%
-26.5%$444.29M$250K-4.0354
VSTM
Verastem
2.0648 of 5 stars
$2.42
-7.4%
$6.33
-161.7%
+10.5%$440.89M$88.52M-5.5049
SABS
SAB Biotherapeutics
2.0333 of 5 stars
$9.88
-4.5%
$20.33
-105.8%
N/A$429.53MN/A0.005Analyst Report
News Coverage
RIGL
Rigel Pharmaceuticals
1.9931 of 5 stars
$2.45
-6.5%
$9.50
-287.8%
-20.5%$418.97M$108.62M-27.22169
CRIS
Curis
1.9398 of 5 stars
$4.49
-6.2%
$19.80
-341.0%
+138.8%$411.33M$10.84M-9.7628Analyst Downgrade
BOLT
Bolt Biotherapeutics
1.9931 of 5 stars
$10.50
-1.0%
$41.00
-290.5%
N/A$391.44M$230K-0.6265Gap Up
CLVS
Clovis Oncology
2.0148 of 5 stars
$2.76
-12.7%
$6.88
-149.1%
-47.9%$358.75M$164.52M-0.98N/ANews Coverage
ZIOP
ZIOPHARM Oncology
2.1031 of 5 stars
$1.22
-8.2%
$3.50
-186.9%
-56.9%$263.70M$150K-2.84105
FBIO
Fortress Biotech
2.0914 of 5 stars
$2.42
-9.5%
$11.00
-354.5%
-12.9%$241.11M$45.60M-5.15111High Trading Volume
XOMA
XOMA
1.7131 of 5 stars
$20.38
-8.9%
$49.00
-140.4%
-38.2%$230.52M$29.39M-101.9010
MTEM
Molecular Templates
2.5814 of 5 stars
$4.05
-8.1%
$13.20
-225.9%
-54.7%$228.06M$18.84M-2.13239Analyst Report
Analyst Revision
News Coverage
SPPI
Spectrum Pharmaceuticals
2.2848 of 5 stars
$1.37
-15.3%
$5.00
-265.0%
-71.9%$224.62M$109.33M-1.28176
This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.